Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and tolerability of PBI-4050 in patients with idiopathic pulmonary fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• PBI-4050

Snippet

Sponsor: Liminal BioSciences Ltd. | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Status: COMPLETED